Literature DB >> 12658907

[Cost reduction with project based prescription of generic ACE inhibitors].

Michael Wolzt1, Gerald Ohrenberger, Berthold Reichardt.   

Abstract

BACKGROUND: Increasing drug costs are an economic burden for the health insurance system. AIM: The regional drug prescription pattern for ACE inhibitors in the Austrian county Burgenland was compared for patients discharged from hospital and those in primary care. Furthermore, the potential cost reduction by voluntary prescription of cheaper generic drugs was estimated in the project "Bessere Therapie zum besseren Preis".
METHODS: Following consensual analysis of the regional cross-sectional study, a cheaper generic of the most cost-intensive class of ACE-inhibitor drugs should be prescribed at internal medicine wards and in primary care. The number of prescriptions for patients from the largest health insurance company BGKK was studied and the costs were calculated.
RESULTS: Of the 1347 patients discharged during October 1999 from internal medicine departments of four different hospitals 879 patients received a total of 1440 cardiovascular drugs. The regional prescription pattern at hospitals matched that of physicians in primary care. Between the second quarter of 2000 and 2001, the prescription of ACE inhibitor drugs increased by project advertising from 23,627 packages by 13.1%, and drug costs in this group were reduced by [symbol: see text] 29,778 in this quarter (7.3% of costs). The number of Enalapril prescriptions increased by 33.4% with a percentual portion of generic Enalapril of 57.3%, and in the rest of Austria by 16.9% with 45.0% generics.
CONCLUSION: Consensus based projects are appropriate pharmacoeconomic interventions to change prescription patterns, increase the use of drugs and reduce the increasing cost requirements.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658907     DOI: 10.1007/BF03040268

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  12 in total

1.  Therapeutic substitution and therapeutic conservatism as cost-containment strategies in primary care: a study of fundholders and non-fundholders.

Authors:  R P Wilson; J Hatcher; S Barton; T Walley
Journal:  Br J Gen Pract       Date:  1999-06       Impact factor: 5.386

2.  Changing doctor prescribing behaviour.

Authors:  P S Gill; M Mäkelä; K M Vermeulen; N Freemantle; G Ryan; C Bond; T Thorsen; F M Haaijer-Ruskamp
Journal:  Pharm World Sci       Date:  1999-08

Review 3.  Patient compliance in the treatment of arterial hypertension.

Authors:  J M Mallion; D Schmitt
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

Review 4.  Adverse events, compliance, and changes in therapy.

Authors:  R Düsing
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.

Authors:  David A Mott; Richard R Cline
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

6.  Prescribing behaviour in general practice: the impact of promoting therapeutically equivalent cheaper medicines.

Authors:  S J Roberts; D N Bateman; J M Smith
Journal:  Br J Gen Pract       Date:  1997-01       Impact factor: 5.386

7.  Identifying patient and physician characteristics that affect compliance with antihypertensive medications.

Authors:  X S Ren; L E Kazis; A Lee; H Zhang; D R Miller
Journal:  J Clin Pharm Ther       Date:  2002-02       Impact factor: 2.512

8.  Patients' perceived problems with hypertension and attitudes towards medical treatment.

Authors:  E Jokisalo; E Kumpusalo; H Enlund; J Takala
Journal:  J Hum Hypertens       Date:  2001-11       Impact factor: 3.012

9.  Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study.

Authors:  R Nuesch; K Schroeder; T Dieterle; B Martina; E Battegay
Journal:  BMJ       Date:  2001-07-21

10.  Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.

Authors:  P McManus; D J Birkett; J Dudley; A Stevens
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Jun-Jul       Impact factor: 2.890

View more
  5 in total

1.  [Generic drugs--medical progress at a moderate price].

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

2.  [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].

Authors:  Ghazaleh Gouya; Berthold Reichardt; Anja Bidner; Robert Weissenfels; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

3.  [Generics in Austria 2003-2008: an update].

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  [Economic public health significance of generic drugs].

Authors:  Doris Tschabitscher; Fabian Waechter; Marcus Müllner
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

5.  The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study.

Authors:  Thomas Grimmsmann; Ulrike Schwabe; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2007-06-05       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.